🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522307-14-00
Completed Phase I

A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma

2025-522307-14-00 · tracked via the Priya Life Science EU tracker
Sponsor
Intas Pharmaceuticals Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
08/12/2025
Enrollment target
34
Sites
Spain, Romania

Condition studied

Melanoma

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522307-14-00 on CTIS ↗ ← All trials in the EU